A rare point of agreement is emerging in the deeply divided debate over U.S. drug policy: both prohibitionists who favor strict enforcement and reformers who advocate for decriminalization say expanded treatment infrastructure is essential to any effective approach.
The convergence comes as overdose deaths continue to claim tens of thousands of American lives annually, with fentanyl involved in more than 55,000 deaths in the past year according to provisional Centers for Disease Control and Prevention data. While advocates acknowledge that disagreement persists on enforcement approaches, they argue that building treatment capacity represents common ground regardless of one's broader philosophy.
What the Right Is Saying
Conservatives who favor strict enforcement also emphasize treatment infrastructure as a critical component of any comprehensive strategy. They argue that prohibition efforts are undermined when individuals struggling with addiction cannot access effective care.
House Judiciary Committee Chairman Rep. Jim Jordan has highlighted the connection between supply-side crackdowns and treatment availability, noting that reduced prescribing of opioid painkillers led many patients to turn to heroin and fentanyl as they sought alternatives for pain management. 'If we're going to disrupt this cycle, people need real options,' Jordan said during a committee hearing last month.
The American Addiction Society and other conservative-aligned recovery organizations have advocated for increased funding for faith-based treatment programs, expansion of peer support networks, and incentives for healthcare workers to enter the substance use treatment field. Republican legislators in several states have introduced bills aimed at increasing inpatient detox capacity and outpatient treatment slots in underserved communities.
What the Left Is Saying
Progressive reformers who have long advocated for treating drug addiction as a public health issue rather than a criminal matter say the treatment infrastructure gap has been evident for decades. They point to Oregon's Measure 110, which removed criminal penalties for possessing small amounts of drugs but faced criticism when fewer than 1 percent of those issued $100 fines completed the offered health assessment.
The measure 'wasn't ready to support the influx of users seeking treatment, even if they wanted it,' wrote Jim Crotty, former deputy chief of staff at the Drug Enforcement Administration, in a recent analysis. Reform advocates have echoed this sentiment, arguing that decriminalization without corresponding investment in services leaves vulnerable populations without pathways to recovery.
Organizations including the Drug Policy Alliance and Shape Your Destiny have pushed for increased federal funding for community-based treatment programs, noting that harm reduction strategies work best when paired with accessible recovery services. Senate Democrats have introduced legislation aimed at expanding Medicaid coverage for substance use treatment and increasing the number of certified addiction counselors nationwide.
What the Numbers Show
The treatment infrastructure gap is substantial by multiple measures. According to federal health data, more than 40 percent of Americans lived in mental health professional shortage areas as of 2025, with demand far exceeding available providers. The shortages are even more acute in rural counties and carceral settings, where substance use disorder rates are disproportionately high.
Approximately 80 percent of U.S. counties lack an opioid treatment program, the only legal venue for obtaining methadone, one of three FDA-approved medications for opioid use disorder. Wyoming has zero such programs statewide. Inpatient detox beds, residential treatment centers, and outpatient clinics remain in short supply nationwide despite growing need.
The CDC reports that synthetic opioids like fentanyl can be more than 50 times as potent as heroin, contributing to the overdose crisis that claimed over 81,000 lives in a recent 12-month period. Treatment professionals say evidence-based medications including methadone, buprenorphine, and naltrexone are proven to reduce mortality and improve recovery outcomes when accessible.
The Bottom Line
The bipartisan focus on treatment infrastructure represents one of few areas where competing drug policy philosophies align. Whether the ultimate approach emphasizes enforcement or decriminalization, experts from multiple perspectives agree that expanding access to evidence-based treatment is a prerequisite for success.
What remains unclear is whether political will exists to fund substantial expansion. Treatment advocates are pushing for increased federal appropriations, loan forgiveness programs for addiction specialists, and streamlined licensing pathways to address workforce shortages. State legislatures in both red and blue states have begun considering measures aimed at increasing capacity, though comprehensive solutions remain elusive. Watch for congressional action on opioid treatment funding as the session progresses.